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Abstract Psoriasis and psoriatic arthritis represent two
paradigmatic conditions characterized by chronic inflam-
mation and possibly autoimmunity, despite the absence of
known serum autoantibodies. The two diseases, albeit
strongly correlated from clinical, genetic, and epidemiog-
ical standpoints, manifest significant differences in terms of
etiology and pathogenetic mechanisms. Nonetheless, Th17
cells appear crucial to both diseases, and IL23 is the
cytokine involved in determining the fate of naive CD4?
cells to differentiate into a pathogenic phenotype. This
basic experimental observation led to a clear understanding
of the immune dysfunction causing psoriasis and psoriatic
arthritis but, more importantly, also led to new therapeutic
approaches. In recent years, monoclonal antibodies direc-
ted to IL12/IL23 (ustekinumab) or IL17 (secukinumab,
ixekizumab, brodalumab) are being investigated or have
proven to be beneficial for patients with psoriatic disease,
thus further supporting the view that Th17 cells play a
pivotal role in disease onset and perpetuation. These most
recent reports indeed represent significant developments
that may allow overcoming the TNFa pathway as the major
therapeutic target in chronic inflammation.
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Introduction
Psoriasis (Pso) and Psoriatic arthritis (PsA) are chronic
inflammatory diseases affecting the skin and the spine or
peripheral joints [1, 2]. Although Pso and PsA show
important differences at immunological and genetic levels,
the prevailing view is that they are different manifestations
of the same disease, with peculiar penetrance and onset
timing. The etiology of both diseases remains largely
unknown, but their genetic, immunological, and environ-
mental bases have been recently elucidated. Both Pso and
PsA markedly reduce the quality of life of affected people
and recent studies have suggested the association of pso-
riatic disease with other pathological conditions [3–12].
Pso is a chronic relapsing dermatitis, characterized by
epidermal hyperplasia, vascular proliferation, and infiltra-
tion of leukocytes in the dermis. It usually presents with
scaly red plaques on typical areas of the body, such as the
scalp, the lumbar and sacral region, and the extensor areas
of elbows and knees. PsA is a chronic seronegative arthritis
that may be diagnosed in the absence of active Pso in the
patient but with a positive history of skin manifestations in
one first degree relative [13, 14]. PsA is characterized by
enthesitis and/or arthritis involving the distal interphalan-
geal, axial joints, commonly with active sacroilitis. Despite
the obvious association between the two conditions, the
mechanisms shared by both diseases remain largely
unknown and specific elements point towards a common
pathogenesis.
The burden of psoriatic disease is shown by the high
prevalence of the disease and its serious impact on the
B. Marinoni  A. Ceribelli  M. S. Massarotti  C. Selmi
Division of Rheumatology and Clinical Immunology, Humanitas
Clinical and Research Center, Rozzano, Milan, Italy
B. Marinoni  A. Ceribelli  C. Selmi
Biometra Department, University of Milan, Milan, Italy
C. Selmi (&)
Division of Rheumatology, Allergy and Clinical Immunology,
Genome and Biomedical Sciences Facility, University of
California at Davis School of Medicine, 451 Health Sciences
Drive, Suite 6510, Davis, CA 95616, USA
e-mail: cfselmi@ucdavis.edu
123
Autoimmun Highlights (2014) 5:9–19
DOI 10.1007/s13317-013-0057-4
quality of life of affected patients. In fact, Pso is found in
2–3 % of the Caucasian population and approximately
30 % of patients with Pso will develop PsA [15]. Even if
the epidemiological profile of PsA is likely to be widely
variable across world areas, the prevalence of PsA is gen-
erally estimated to be between 0.3 and 1 % of the general
population [2]. In approximately 75 % of the cases the skin
disease precedes arthritis, while in 15 % of patients Pso
appears after PsA and in 10 % the cutaneous and articular
involvement are simultaneous [16]. Most frequently, Pso
appears around 15–35 years of age, while PsA is highly
polymorphic and can occur at any age, in both adults and
children, with a peak in the 40–50 years range [17]. Its
frequency is similar in both sexes, but men are 3–5 times
more likely to manifest a spine involvement [7].
An open issue in both Pso and PsA is that, although
current therapies have improved the clinical management,
unmet clinical needs still remain. In fact, many patients
treated with disease-modifying anti-rheumatic drugs
(DMARDs) and TNFa inhibitors may show limited drug
tolerance, partial or non-responsiveness, and the long-term
use of systemic therapies, such as anti-inflammatory drugs
and corticosteroids, is burdened by the risk of serious
adverse events. For these reasons, recent efforts in clinical
research have focused on the development of new therapies
targeting more specifically the pathogenetic mechanisms of
psoriatic disease, not only to achieve clinical remission but
also to reduce the progression of Pso and PsA. In partic-
ular, based on recent insights into the immunopathogenesis
of Pso and PsA, the quest for novel therapeutic targets has
identified the IL23/Th17 axis as a promising target for
specific interventions to inhibit the dysregulated immune
system. This major breakthrough is well illustrated by
biological therapies targeting IL17A (ixekizumab and
secukinumab), IL17R (brodalumab), and IL12/IL23 (us-
tekinumab) that have been or are being evaluated at
advanced stages of development.
Immunopathogenesis of psoriatic disease
Pso and PsA are the two major manifestations of the pso-
riatic disease spectrum and are believed to share a common
pathophysiological pathway characterized by dysfunctional
stromal immune cell and cytokine network causing
inflammation in the skin, entheses, and joints [18]. The
major cytokines involved in Pso and PsA are listed in
Table 1. In the earliest phases of research, psoriatic disease
was considered to be the result of a Th1 response with
IFNc and IL12 as signature cytokines [19]. In recent years,
however, the key role of both the innate immune cells in
the affected tissue and adaptive Th17 cells response toge-
ther with other cytokines (i.e. TNFa, IL23, IL17, IL22) has
been clarified. The major contributors to the initiation of
the local inflammation and the activation of IL23/Th17 axis
appear to be myeloid dendritic cells (mDC) [20]. On the
other hand, it has been proposed that IFNa-producing
plasmacytoid DC (pDC) [21], LL37 produced by kerati-
nocytes in Pso, mechanical stress [22], and microbial
infections [22] contribute to the stimulus that induces DC
and other innate immunity cells to trigger inflammation. In
clinical terms, these phenomena could explain the wide
variability of the disease phenotype and the association
with environmental factors. Among the proposed factors,
the endogenous antimicrobial peptide LL37 released by
keratinocytes plays a relevant role in linking the innate and
adaptive immunity in Pso as LL37 aggregates with
autogenous DNA and activates toll-like receptor (TLR)
nine signaling in pDC, thus resulting in the production by
mDC of the pro-inflammatory cytokines TNFa, IL6, IL23,
and IFNc [22]. The local milieu enriched with these
cytokines that are produced also by local macrophages
further promotes the Th17 polarization of naı¨ve CD4? Th
cells in lymph nodes, triggered by an unknown antigen
stimulation [23, 24]. Once activated, Th17 cells migrate to
the inflamed tissues, overexpressing the chemokine CCL20
and binding to its receptor CCR6 and perpetuate the
immune reaction by attracting neutrophils to the site of
inflammation.
In Pso, the effector cytokines IL17, IL22, and IL20
produced by Th17 cells activate the STAT3 signaling in
keratinocytes, inducing their hyperproliferation and the
expression of proinflammatory cytokines, growth factors,
antimicrobial peptides, and matrix metalloproteinases that
cause chronic skin and articular inflammation [24]. In PsA,
Th1- and Th17-driven inflammation is more likely to exert
a pro-erosive influence and cause the ultimate damage to
the involved joints. In fact, proinflammatory cytokines (i.e.
IL23, TNFa, and IL17) activate the NFkB pathway in
fibroblasts and synovial cells and induce RANKL and
M-CSF expression that promotes osteoclastogenesis and
bone absorption, thus leading to destructive arthritis [25,
26]. In this scenario, it is unclear whether other factors such
as osteoprotegerin and RANKL levels are increased in PsA
[26]. Hyperplasia of synovial lining cells and mononuclear
cell infiltration (macrophages, neutrophils, T cells) char-
acterize PsA synovitis and could result from these
inflammatory components [27].
The IL23/Th17 axis
A schematic representation of the IL23/Th17 axis is illus-
trated in Fig. 1. Th17 cells are involved in the pathogenesis
of various autoimmune and inflammatory disorders, such
as rheumatoid arthritis (RA), Crohn’s disease (CD),
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asthma, and experimental autoimmune encephalitis (EAE)
as a model of multiple sclerosis [27, 28]. IL23 is the
upstream cytokine crucial for the development and main-
tenance of a pathogenic Th17 cell phenotype from naive
CD4? T cells, together with TGFb and IL6 [23]. IL23
produced by DC and macrophages binds the IL23R on
activated Th17 cells and enhances the expression of the
orphan nuclear receptor c-t (RORc-t), the major tran-
scription factor of Th17 polarization [29]. RORc-t then
further interacts with IL6 induced-STAT3 signaling to
stimulate the production of the effector cytokines IL17A,
IL17F, IL21, and IL22. Once recruited to the site of
inflammation via CCR6-CCL20 chemotaxis, Th17 cells
exert their function via cytokines (i.e. IL17, IL21, IL22)
that activate signaling pathways on different cells [30]. A
recent breakthrough in understanding the pathogenesis of
Pso has been made with studies that successfully showed
the interaction between the IL23/Th17 axis, keratinocytes,
and synovial cells [31]. One downstream cytokine induced
by IL23 acting on Th17 cells is indeed IL17 [32] that takes
part to mechanisms of delayed immune response to recruit
monocytes and neutrophils at sites of inflammation,
causing destructive tissue damage [33]. A well-known
effect of IL17 is the pro-inflammatory ability to induce
airway modifications that has been observed in asthma.
Additional functions of IL17 have been related to induction
of cytokines and prostaglandins that are involved in auto-
immune and inflammatory diseases such as RA and allo-
graft rejection. Other groups also identified an IL23-
independent pathway for IL17 production, mainly medi-
ated by TGFb and IL6 [34], but IL23 is still required to
promote survival and proliferation of the T cells that pro-
duce IL17 [34].
A recent study on Th17 development identified serum
glucocorticoid kinase-1 (SGK1) as an essential node in the
induction of pathogenic Th17 cells. SGK1 is a serine-
threonine kinase that is expressed by differentiating Th17
subsets under IL23R signaling and is critical for Th17
stabilization. The experimental study used an elegant
approach to demonstrate that SGK1 expression is induced
and maintained by exposure to IL23 under Th17 differen-
tiating conditions and is not induced by other T cell subsets
(Th0, Th1, Th2). Nonetheless, it was suggested that SGK1
acts by deactivating Foxo1, a direct inhibitor of IL23R
Table 1 Cytokines involved in Pso and PsA [80–83]
Cytokine Cellular source Receptor Targets Role in Pso/PsA
IL1b Macrophages, T cells ILR1 Keratinocytes,
FLS, ECs, OB
Inflammation, osteoclastogenesis, angiogenesis, Th17
amplification



















Inflammation, neutrophil recruitment, osteoclastogenesis,
angiogenesis




Th17, mDC, OC Th17 differentiation, mDC activation, osteoclastogenesis
IL20 Monocytes IL20Ra/b Th17 Inflammation




Host defence, Keratinocytes and FB proliferation, inflammation








Proinflammatory, DC activation, immune cells recruitment,
angiogenesis Keratinocyte proliferation, osteoclastogenesis,
Th17 amplification
IFNa pDC IFNaR mDC Initation of immune response









Keratinocyte proliferation, inflammation, Th17 differentiation,
angiogenesis
RANKL T cells, FB, FLS, OB RANK Synovial lining
layer
Osteoclastogenesis





DC dendritic cell, FB fibroblasts, FLS fibroblast like synoviocytes, OB osteoblasts, OC osteoclasts, EC endothelial cells, pDC plasmacytoid
dencritic cells, NK natural killer cells, OPG osteoprotegerin
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expression, thus enhancing the expression of IL23R and
stabilizing Th17 phenotype. Interestingly, SGK1 was also
reported to act as a salt-sensing kinase, mediator for
sodium homeostasis, by phosphorylating epithelial sodium
channels (ENaC). A high sodium diet thus enhances the
expression of SGK1 and increases Th17 differentiation
in vitro and in vivo, thus accelerating the development of
autoimmunity. These data raise the issue of whether high
sodium salt intake in western diet is responsible for an
increased pathogenic Th17 response and increase in auto-
immune diseases [35].
The IL23/Th17 axis in Pso and PsA
The first evidence of a major T cell involvement in Pso was
provided by the significant clinical response of patients
treated with earlier T-cells suppressor agents, such as
cyclosporine and alefacept [36, 37], and later costimulation
inhibitors such as abatacept [38]. Moreover, psoriatic pla-
que samples show a marked infiltration of activated T cells
which directly correlate with psoriasis area score index
(PASI). Similar to cutaneous psoriatic eruptions, significant
infiltration of the inflamed synovial membrane by activated
CD4? T cells is also observed in PsA, but the involvement
of Th17 axis in PsA remains unclear [39]. Nonetheless,
signature cytokines of Th17 cells, such as IL17 and IL22,
are highly expressed in skin lesions, joints, and serum of
patients with psoriatic disease and correlate with disease
severity [40]. As shown in Table 2, the critical role of the
Th17 cytokines in Pso is further supported by data from
genomewide association studies (GWAS) that identified
Pso susceptibility genes among those involved in IL23/
Th17 axis, such as IL23R, IL12B, IL23A, TRAF3IP2, and
Act1, which regulate IL17 production and IL17-mediated
signaling [41, 42]. From a genetic standpoint, however, one
concern is related to the difficulty to dissect associations
with Pso from those more pertinent to PsA. Finally, com-
pelling evidence of the critical role of IL23/Th17 axis in
Pso pathogenesis is provided by clinical studies with new
biological agents, as will be discussed further in a dedi-
cated section.
IL23 is a member of the IL12 family of cytokines. It is a
heterodimeric cytokine composed of the same IL12 subunit
called p40 paired with its unique subunit p19 [43]. IL23 is
mainly produced by mDC, and in Pso it is upregulated and
responsible for the priming of the Th17 response [23],
playing a key role in the pathogenesis of skin lesions [44].
Fig. 1 A schematic representation of the Th17 pathway and its involvement in psoriatic disease
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The presence of abundant IL23? DC as well as the ele-
vated mRNA expression of both IL23 subunits (IL23p19
and IL23p40) in psoriatic lesions supports this hypothesis.
The role of IL23 in the induction of Pso is confirmed also
experimentally by the effect of injecting IL23 in the mouse
skin, resulting in epidermal hyperplasia and inflammatory
cellular infiltration similar to human Pso, mediated by
TNF-a, IL22, IL17A, and IL17F [45]. Studies on experi-
mental models of arthritis have also demonstrated that IL23
affects osteoclastogenesis via an IL17-independent mech-
anism [46]. The use of therapies such as IL23 inhibitors is
associated with reductions of the inflammation, with ther-
apeutic functions similar to those already known from anti-
TNFa agents used in PsA like etanercept [47].
IL17 and IL22 are the main effector cytokines of the
Th17 polarization and are of primary importance in the
protection against bacterial and fungal infections [20]. IL17
is part of the IL17 cytokine family, which consists of six
members: IL17A, IL17B, IL17C, IL17D, IL17E/IL25, and
IL17F (Table 3). Because of their structural and functional
similarities and the fact that they are both produced by
Th17 cells, IL17A and IL-17F have been most thoroughly
studied and characterized. IL17A and IL17F are most
closely related, sharing 55 % homology with each other.
Both are active as homodimers, and recently, IL17A/IL17F
heterodimers have been identified, and their function is
currently being studied [48]. In addition to Th17, other
sources of IL17 are mast cells [22], cytotoxic CD8? T
cells, natural killer cells, neutrophils, and macrophages
[49]. IL17 induces the expression of pro-inflammatory
cytokines and chemokines via IL17R, which recruits neu-
trophils to inflammatory sites. IL17 is especially relevant in
the protection of mucocutaneous surfaces against Candida
albicans infection. Recent genetic studies demonstrated
that rare human genetic diseases associated with chronic
mucocutaneous candidiasis are linked to genetic defects in
IL17 signaling, either through autosomal IL17RA or IL17F
mutations (i.e. chronic mucocutaneous candidiasis) [50] or
high titers of neutralizing antibodies against IL17 cytokines
(i.e. autoimmune polyendocrine syndrome type 1, APS-I,
secondary to mutations in the AIRE gene) and mutation in
STAT3 signaling (i.e. hyper-IgE syndrome) [51]. Thus, an
impaired immunity and a deficient Th17 response are
responsible for chronic mucocutaneous candidiasis among
individuals not only with primary but also acquired
immunodeficiency, such as HIV/AIDS, chemotherapy-
induced neutropenia, and those assuming chronic systemic
corticosteroid therapies or drugs targeting the IL23/Th17/
IL17 pathway [52].
IL22 is a member of the IL10 family of cytokines, which
also includes IL19, IL20, and IL24 [22]. IL22 activates
IL22R and IL10R2 signaling and induces the release of
antimicrobial peptides and matrix metalloproteinases from
fibroblasts, endothelial cells, epithelial cells, osteoblasts,
macrophages, and DC [20, 21]. An increasing body of
evidence suggests that IL17 and IL22 are also important in
Pso pathogenesis based on the observation that serum
levels of IL17 and IL22 are elevated compared with heal-
thy controls and correlate with disease severity [53, 54].
Moreover, IL17 and IL22 induce the expression of
Table 2 Susceptibility genes involved in Pso and PsA from GWA studies
Gene Name Chromosome Pathway Other diseases References
IL23A IL23 p19 12q13 IL23 [42]
IL12B IL12/IL23 p40 5q33 IL23 IBD, PsA, AS, MS [42, 53, 84–86]
IL23R IL23R 1p31 IL23 IBD, PsA, AS [42, 53, 87, 88]
TYK2 Tyrosine kinase 2 19p13 IL23 IBD, SLE, MS? [89–92]
TRAF3IP2 TNF receptor-associated factor 3 interacting protein 2 6q21 NFKB, IL17 PsA, RA, CD [92–96]
TNFA IP3 TNFa-induced protein3 6q23 NFKB PsA, SLE, RA, CD [42, 95, 97, 98]
TNIP1 TNFAIP3-interacting protein 1 5q33 NFKB PsA, SLE, SSc [42, 99, 100]
DEFB4 Defensin b 4 16q12 IL17 [101]
IBD inflammatory bowel disease, PsA psoriatic arthritis, AS ankylosing spondylitis, MS multiple sclerosis, CD celiac disease, RA rheumatoid
arthritis, SLE systemic lupus erythematous, SSc systemic sclerosis
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antimicrobial peptides in Pso, such as psoriasin (S100A7),
koebnerisin (S100A15), b-defensin 2, S100A8, and
S100A9 [55] that can act synergistically as chemoattrac-
tants to amplify inflammation [56]. The expression of the
neutrophil chemoattractants CXCL1, CXCL3, CXCL5,
CXCL6, CXCL8, and the chemokine CCL20 is also
upregulated by IL17 [37] and likely promotes skin
inflammation. In particular, IL17 exerts a pro-inflammatory
activity, and IL22 mainly acts on keratinocytes via STAT3
activation [40]. In Pso, IL22 also induces the proliferation
and hyperplasia of keratinocytes, mediates the production
of antimicrobial peptides, and alters differentiation of
keratinocytes’ leading to hypogranulosis, achantosis, and
pankeratosis [57]. In the case of PsA, experimental evi-
dence supporting a role of IL17A in PsA is limited com-
pared with Pso or RA. Th17 cells are increased in the
peripheral blood of patients with PsA, and they exhibit a
highly differentiated and polyfunctional phenotype sug-
gesting that they play a specific role in the disease [58].
IL17A—producing cells, including Th17 cells and c-Kit—
positive mast cells, are increased in the synovial fluid
during the course of active PsA [4, 59], and synovial
fibroblasts produce higher levels of IL6, CXCL8, and
MMP-3 in response to IL17A compared with cells from
osteoarthritis patients, an effect that can be blocked by an
anti-IL17RA monoclonal antibody. IL17 influences all
critical events of inflammation which include induction of
adhesion molecules such as ICAM-1, upregulation of
chemokines (i.e. IL6, IL8), and angiogenesis. In vitro
studies demonstrated that IL17 can induce the expression
of RANKL and influence osteoclastogenesis in PsA [47,
60].
New therapeutic targets in Pso and PsA
IL23 targeting (briakinumab and ustekinumab)
Briakinumab and ustekinumab are two fully human
monoclonal antibody (mAb), directed at the p40 subunit
shared by IL12 and IL23 (Table 4).
Ustekinumab was approved by the FDA for Pso and PsA
after demonstration of its efficacy and safety profile in
phase III clinical trials. Two placebo-controlled trials,
PHOENIX 1 and PHOENIX 2, in fact, showed that us-
tekinumab was able to ameliorate Pso plaques, pruritus,
and nail psoriasis [31]. More importantly, the head-to-head
ACCEPT [Active Comparator (CNTO 1275/Enbrel) Pso-
riasis Trial] study was an active comparator randomized
phase III trial against etanercept in the treatment of Pso,
where 903 patients with moderate-to-severe Pso received
subcutaneous injections of either 45 or 90 mg of us-
tekinumab (at weeks 0 and 4) or high-dose etanercept
(50 mg twice weekly for 12 weeks). At the primary end-
point of 12 weeks, the proportions of patients achieving a
PASI75 response in the ustekinumab 45 mg group, us-
tekinumab 90 mg group, and etanercept 50 mg group were
68, 74 and 57 %, respectively (P = 0.01 and P \ 0.001,
respectively) [61]. In all trials, ustekinumab at the dosage
of 45 or 90 mg significantly improved clinical symptoms
of Pso compared with placebo or etanercept. Ustekinumab
was generally well tolerated, as most adverse events were
mild and did not require treatment adjustment, and the
incidence of serious AE was 2 % or less for all treatment
arms. In a pooled analysis of data from phase II and III
clinical studies investigating the incidence of major
adverse cardiovascular events (myocardial infarction,
stroke or cardiovascular death) with ustekinumab treatment
in patients with moderate to severe Pso, this adverse event
was reported in 0.3 % of ustekinumab-treated patients [62].
Nonetheless, ustekinumab may increase the risk of infec-
tions or reactivate latent infections [63, 64]. Ustekinumab
was approved in 2009 in the US [64] for the treatment of
adult patients with moderate-to-severe plaque Pso, while in
the European Union [63] ustekinumab is approved for
patients who failed to respond to, have a contraindication
to, or are intolerant to other systemic therapies or photo-
therapy for Pso. In the case of PsA, the Food and Drug
Administration (FDA) and EU approved ustekinumab in
2013 for treatment of adults with active PsA who have not
responded adequately to previous DMARDs. The approval
was supported by findings from two phase III multicenter,
Table 4 Overview of current and ongoing studies on biological therapies targeting IL17 or IL23 [69–79]
Biologic Target Route Pso status/trial PsA status/trial

















14 Autoimmun Highlights (2014) 5:9–19
123
randomized, double-blind, placebo-controlled trials in
naive subjects with active PsA (PSUMMIT1) and in
patients previously treated with biological anti-TNFa
agents (PSUMMIT II) [65]. These studies compared the
efficacy and safety of subcutaneously administered us-
tekinumab 45 or 90 mg at weeks 0, 4, and then every
12 weeks and included 927 patients diagnosed with active
PsA who had at least five tender and five swollen joints and
C-reactive protein levels of at least 0.3 mg/dL. PSUMMIT
II also included 180 patients with previous exposure to at
least one TNFa inhibitor. Results from PSUMMIT I
demonstrated that at week 24, 42 and 50 % of patients
receiving ustekinumab 45 and 90 mg, respectively,
achieved ACR20, the primary endpoint [65]. In PSUMMIT
II, 44 % of patients receiving ustekinumab 45 mg and
44 % of patients receiving ustekinumab 90 mg achieved
ACR20 at week 24. Additionally, ustekinumab improved
soft tissue components of the disease, including dactylitis,
enthesitis, and skin involvement as measured by PASI75
[65]. For the treatment of PsA, ustekinumab is adminis-
tered as a 45-mg subcutaneous injection at weeks 0 and 4,
and then every 12 weeks. For patients with co-existent
moderate to severe plaque Pso weighing more than 220 lbs
(100 kg) the recommended dose is 90 mg subcutaneous
injection at weeks 0 and 4, and then every 12 weeks [66].
On the other hand, briakinumab first showed its efficacy in
one phase II and different phase III studies for the treat-
ment of patients with moderate-to-severe chronic plaque
Pso [67]. In a phase III, 12-week study, 347 patients were
randomized in a 2:2:1 ratio to receive 200 mg briakinumab
at weeks 0 and 4 followed by 100 mg briakinumab at week
8 (n = 138); 50 mg of etanercept twice weekly 3–4 days
apart at weeks 0–11 (n = 141); or placebo injections
matching active treatment (n = 68). Briakinumab showed
an efficacy superior to both placebo and etanercept at
12 weeks. At the primary end point of week 12, the pro-
portion of patients achieving a Physician’s Global
Assessment (PGA) of 0/1 in the briakinumab group, eta-
nercept group, and placebo group were 71, 39.7 and 2.9 %,
respectively (p \ 0,001). Furthermore, at 12 weeks the
proportion of patients receiving a PASI75 response in the
briakinumab group, etanercept group, and placebo group
was 81.9, 56.0, and 7.4 %, respectively (p \ 0,001). Seri-
ous adverse event rates were reported in four patients
receiving briakinumab (2.9 %), one patient receiving eta-
nercept (0.7 %), and one placebo-treated patient (1.5 %)
[67], and, due to adverse cardiovascular effects, bria-
kinumab was ultimately withdrawn [68].
IL17 targeting (secukinumab, ixekizumab, brodalumab)
Three main molecules target IL17 and are being studied for
psoriatic disease (Table 4). Response rates with IL17
pathway inhibition vary and these different degrees of
response suggest that IL17-mediated pathways play a role
in both diseases, but to different, yet to be defined, extents.
IL17 inhibitors include secukinumab, a highly selective,
fully human IgG1 k mAb directed against the IL-17A
cytokine; ixekizumab, a humanized IgG4 anti-IL-17A
mAb; and brodalumab, a fully human IgG2 anti-IL-17RA
mAb.
Secukinumab (AIN457) is an anti-IL-17A ligand
monoclonal antibody approved by the FDA for the treat-
ment of Pso, RA, chronic non-infectious uveitis, and CD. A
phase I study in 36 patients with Pso demonstrated that a
single dose of secukinumab at 3 mg/kg significantly
reduced disease severity (mean PASI score) by 63 % at
week 12 versus 9 % for placebo. Clinical responses were
associated with reduction in epidermal hyperplasia, IL17-
producing cells, and the gene expression of various cyto-
kines and chemokines (e.g., IL17A, IL21, IL22, CCL20,
KRT16, and DEFB4) [69]. Data from three phase II studies
reported 12-week PASI75 response rates of 81 % in patients
with Pso treated with subcutaneous secukinumab at 150 mg
(three or four doses) and 83 % in patients treated with
intravenous secukinumab [70]. The safety and efficacy of
secukinumab in PsA were evaluated in a double-blind,
placebo-controlled phase IIA study, in which 42 patients
were randomized to treatment with two doses of subcuta-
neous secukinumab at 10 mg/kg, given 3 weeks apart, or
placebo [35]. The ACR20 response rates at week 6 were the
primary endpoint and were 39 % with secukinumab com-
pared with 23 % for placebo, failing to reach a statistical
significance. The ACR20 response at weeks 12 and 28 for
secukinumab was observed in 39 and 43 %, and for pla-
cebo, 15 and 18 % of patients, respectively. FUTURE 1, a
Phase III randomized, double-blind, placebo-controlled,
multicenter study to assess the efficacy and safety of sec-
ukinumab in patients with active PsA who were intolerant
to or had an inadequate response to anti-inflammatory
drugs, DMARDs and/or TNFa inhibitor therapy is ongoing.
Ixekizumab (LY2439821) is a humanized monoclonal
antibody directed at IL17A that is being investigated for
the treatment of Pso and RA [4]. Recent data from a phase
II study in Pso showed week 12 PASI75 response rates of
77, 83, and 82 % following administration of subcutaneous
ixekinumab at 25, 75, and 150 mg (weeks 0, 2, 4, 8, and
12), respectively, versus 7.7 % for placebo. Importantly, up
to 72 % of patients in the active-treatment groups achieved
clear or almost clear Pso status according to Physician’s
Global Assessment [71]. Ixekizumab is undergoing evalu-
ation as a treatment for moderate-to-severe Pso also in
three phase III studies (UNCOVER-1, -2 and -3) to be
completed between February 2018 and April 2019. In
detail, UNCOVER-1 is a multicenter, randomized, double-
blind, placebo-controlled study characterized by a dosing
Autoimmun Highlights (2014) 5:9–19 15
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period followed by a randomized maintenance dosing
period and a long-term extension period, to evaluate the
efficacy and safety of ixekizumab in patients with moder-
ate-to-severe plaque Pso. UNCOVER-2 is a multicenter,
randomized, double-blind, placebo-controlled study in
which a comparison of efficacy and safety of ixekizumab is
performed with etanercept and placebo in patients with
moderate-to-severe plaque Pso [72]. UNCOVER-3 is a
12-week multicenter, randomized, double-blind, placebo-
controlled study comparing the efficacy and safety of ix-
ekizumab to etanercept and placebo in patients with
moderate-to-severe plaque Pso with a long-term extension
period [73]. On the other hand, SPIRIT-P1 is a phase III
study of Ixekizumab that is currently enrolling patients
with active PsA in a multicenter, randomized, double-
blind, active, and placebo-controlled 24-week study fol-
lowed by long-term evaluation of efficacy and safety of
ixekizumab in biologic DMARD-naive patients with active
PsA [74].
Finally, brodalumab (AMG 827) is an IL17RA fully
human monoclonal antibody that is under investigation for
a number of inflammatory conditions, including Pso, PsA,
and asthma. A phase I proof-of-concept study in patients
with Pso demonstrated significant improvement in the
major clinical parameters with 7/8 and 5/8 patients
achieving PASI75 by week 6 in the high (700 mg intra-
venous) and moderate (350 mg subcutaneous) single-dose
groups. Improvement in histopathological parameters
included reduction in epidermal thickness, Ki-67 [75], and
keratin-16 gene expression, and infiltrating leukocyte
subsets. In a phase II dose-ranging study, brodalumab (70,
140, or 210 mg at weeks 0, 1, and 2, then every other week
or 280 mg monthly) produced dose-dependent improve-
ment in PASI and Physician’s Global Assessment respon-
ses [76]. Significant mean PASI improvements were
observed at week 12 in 45, 86, 86, and 76 % in the brod-
alumab 70-, 140-, 210-, and 280-mg groups, respectively,
compared with 16 % in the placebo group. PASI75
responses were observed in 33, 77, 82, and 67 % of
patients, respectively, in the brodalumab groups and 0 % in
the placebo group. Brodalumab is currently undergoing
evaluation in three Phase III studies, AMAGINE-1, -2, and
-3. In particular, AMAGINE-1 evaluates the efficacy,
safety, and effect of withdrawal and retreatment with
brodalumab in subjects with moderate-to-severe plaque
Pso, with a completion date estimated in March 2014 [77].
AMAGINE-2 and -3 are two Phase III studies to evaluate
the efficacy and safety of induction and maintenance reg-
imens of brodalumab compared with placebo and us-
tekinumab in subjects with moderate-to-severe plaque Pso
[78, 79]. AMAGINE-2 is currently enrolling patients,
while AMAGINE -3 is ongoing and the estimated com-
pletion date is September 2014.
Final remarks and future directions
Recent findings strongly support the view that the Th17
pathway plays a predominant role in Pso and PsA patho-
genesis, similar to multiple sclerosis, and animal models
should contribute to unravel new details on this promising
field of research and potential therapeutic implications.
New therapies targeting the pivotal IL23 and the effector
IL17 have been developed with promising results. In par-
ticular, successful data have been observed by blocking
IL23 and IL12 with ustekinumab, later approved for
treatment of Pso and most recently PsA, and by blocking
IL17 with monoclonal antibodies in phase III trials.
Overcoming TNFa as a unique target for Pso and PsA and
identifying new pathways to tackle chronic inflammation
are mandatory priorities to reduce the risk of partial or
temporary response. Furthermore, the development of safer
and more effective drugs has opened the way to more
selective interventions that arrest the disease progression
by blocking the basis of the pathological mechanism of the
psoriatic disease. Of note, comorbidities are also expected
to mitigate from the new treatments and this advantage
should be considered in the approval process of new
molecules. However, the pharmacological research into the
Th17 pathway maintains numerous promising develop-
ments and the axis is a solid horizon for future solutions. In
this scenario, possibly more than in any other field of
biomedical research, a conjunct effort of clinicians and
basic scientists is a necessary step to achieve significant
results. Finally, additional and sometimes unsuspected
factors, such as dietary salt intake or weight changes,
should be taken into account for future trials as determi-
nants of clinical response.
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